This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the KOMET-007 Trial of ziftomenib, a menin inhibitor being developed by Kura Oncology for the treatment of AML.
Ticker(s): KURAWho's the expert?
Institution: Cancer Care Centers of South Texas
Hematologist/Oncologist at Cancer Care Centers of South Texas and Clinical Associate Professor in Medicine at the University of Texas Health Science Center at San Antonio.
Currently treats 10-12 patients with Follicular lymphoma and/or refractory B-cell non-Hodgkin lymphoma
Specializing in the management of all adult solid tumors, lymphomas and leukemias.
Interview Goalto discuss the current standard of care and the potential of ziftomenib, a menin inhibitor being developed by Kura Oncology for the treatment of AML.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
